Alembic Pharma gets USFDA nod for generic cancer treatment injection:

Alembic Pharma gets USFDA nod for generic cancer treatment injection:

Daily Current Affairs   /   Alembic Pharma gets USFDA nod for generic cancer treatment injection:

Change Language English Hindi

Category : Science and Tech Published on: July 02 2025

Share on facebook

Alembic Pharmaceuticals has secured final approval from the USFDA for its generic Doxorubicin Hydrochloride Liposome injection (20 mg/10 mL and 50 mg/25 mL). This key oncology treatment approval under ANDA allows Alembic to market a cost-effective alternative for various cancers in the US.

Recent Post's

  • WAVEX Start-up Challenge 2025 launched to build AI-based multilingual platform ‘BhashaSetu’.

    Read More....

  • In 2024, India added 683 animal species and 433 plant taxa to its biodiversity record.

    Read More....

  • ITI to implement ₹1,901 crore BharatNet Phase-3 project in North Eastern Region.

    Read More....

  • Alembic Pharma gets USFDA approval for generic cancer drug Doxorubicin Liposome.

    Read More....

  • MiPhi becomes first Indian firm to design and manufacture enterprise-grade SSDs.

    Read More....

  • Ayush Shetty wins US Open 2025; Tanvi Sharma ends runner-up in women’s singles.

    Read More....

  • Lando Norris wins Austrian Grand Prix 2025; Verstappen retires mid-race.

    Read More....

  • India’s FY25 GST collection hits all-time high of ₹22.08 lakh crore, doubling in five years.

    Read More....

  • India restricts import of jute and fabrics from Bangladesh to Nhava Sheva seaport only.

    Read More....

  • Reliance Defence signs ₹20,000 crore pact with US firm for military MRO services.

    Read More....

2025 © and Powered By Graposs Edutech Private Limited

Terms & Condition Privacy Policy Disclaimer